CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 17 enrolled
Drug / intervention
salsalatedrug
Likely dose
salsalate 3gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01578486
NCT01578486Phase 4Completed
CompareCT.gov

Salsalate as an Adjunctive Treatment for Patients With Schizophrenia

University of Massachusetts, Worcester·interventional·Posted Apr 17, 2012·Updated May 8, 2018

In Brief

A Phase 4 clinical trial evaluating salsalate for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This is a 12-week, open-label trial of salsalate 3 g/day as an adjunctive treatment in 15 schizophrenia subjects to examine salsalate's effect on psychopathology, cognitive functioning, and metabolic parameters. Potential subjects will be identified by their clinicians at the Freedom Trail Clinic, or Massachusetts General Hospital. A total of 15 subjects will be enrolled.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 17, 2012
Enrollment StartJun 1, 2011
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 14.2 years ago

Interventions

salsalatedrug

open-label trial of salsalate 3g/day for 12 weeks.